$8.11
0.43% day before yesterday
Nasdaq, May 30, 09:47 pm CET
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Ocular Therapeutix Inc Stock price

$8.01
-0.29 3.49% 1M
-1.76 18.01% 6M
-0.53 6.21% YTD
+2.21 38.10% 1Y
+4.82 151.10% 3Y
+0.87 12.18% 5Y
-16.02 66.67% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.13 1.60%
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Key metrics

Market capitalization $1.28b
Enterprise Value $995.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.69
P/S ratio (TTM) P/S ratio 21.39
P/B ratio (TTM) P/B ratio 4.80
Revenue growth (TTM) Revenue growth -0.33%
Revenue (TTM) Revenue $59.65m
EBIT (operating result TTM) EBIT $-204.08m
Free Cash Flow (TTM) Free Cash Flow $-148.43m
Cash position $349.68m
EPS (TTM) EPS $-1.15
P/E forward negative
P/S forward 22.82
EV/Sales forward 17.81
Short interest 8.72%
Show more

Is Ocular Therapeutix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Ocular Therapeutix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Ocular Therapeutix Inc forecast:

13x Buy
100%

Analyst Opinions

13 Analysts have issued a Ocular Therapeutix Inc forecast:

Buy
100%

Financial data from Ocular Therapeutix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
60 60
0% 0%
100%
- Direct Costs 5.56 5.56
3% 3%
9%
54 54
1% 1%
91%
- Selling and Administrative Expenses 108 108
37% 37%
182%
- Research and Development Expense 150 150
123% 123%
251%
-200 -200
127% 127%
-336%
- Depreciation and Amortization 3.85 3.85
13% 13%
6%
EBIT (Operating Income) EBIT -204 -204
123% 123%
-342%
Net Profit -193 -193
67% 67%
-323%

In millions USD.

Don't miss a Thing! We will send you all news about Ocular Therapeutix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocular Therapeutix Inc Stock News

Neutral
GlobeNewsWire
18 days ago
BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025.
Neutral
GlobeNewsWire
about 2 months ago
BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Executive Director, Payer Access, Thomas J. Cella, and one other newly hired non-executive employee. The awards were made as inducements materi...
Neutral
GlobeNewsWire
2 months ago
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April:
More Ocular Therapeutix Inc News

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Head office United States
CEO Pravin Dugel
Employees 274
Founded 2006
Website www.ocutx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today